Primary Membranous Nephropathy Clinical Trial
Official title:
A Phase 2/3, Multicenter, Randomized, Active-Controlled, Open-label Study to Evaluate the Efficacy and Safety of Zanubrutinib in Patients With Primary Membranous Nephropathy
The primary objectives of this study are: In Part 1 to evaluate the efficacy of zanubrutinib as measured by proteinuria reduction, and in Part 2 to evaluate the efficacy of zanubrutinib compared with tacrolimus as measured by complete remission rate, in participants with primary membranous nephropathy who are on optimal supportive care.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05800873 -
Evaluate The Efficacy, Safety, Pharmacokinetics And Pharmacodynamics Of EVER001
|
Phase 1 | |
| Recruiting |
NCT05514015 -
Clinical Study of Rituximab Combined With Corticosteroids or Rituximab Monotherapy in the Treatment of Primary Membranous Nephropathy
|
Phase 4 | |
| Recruiting |
NCT05668403 -
A Phase I Clinical Study of Recombinant Humanized Anti-CD20(B-lymphocyte Antigen CD20) Monoclonal Antibody Subcutaneous Injection in the Treatment of Primary Membranous Nephropathy
|
Phase 1 | |
| Recruiting |
NCT05696613 -
A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy
|
Phase 3 | |
| Active, not recruiting |
NCT04629248 -
A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy
|
Phase 3 | |
| Recruiting |
NCT05862233 -
A Clinical Study of MIL62 in Primary Membranous Nephropathy
|
Phase 3 | |
| Not yet recruiting |
NCT06120673 -
REmission in Membranous Nephropathy International Trial (REMIT)
|
Phase 3 | |
| Recruiting |
NCT05398653 -
A Clinical Study of MIL62 in Primary Membranous Nephropathy
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT05136456 -
Evaluate the Efficacy and Safety of SHR1459 Tablets in Patients With Primary Membranous Nephropathy
|
Phase 2 |